Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK | Market Cap | 21.31B -28.6% |
| Revenue (ttm) | 4.64B -49.0% |
| Net Income | 2.74B -59.0% |
| EPS | 38.53 -58.9% |
| Shares Out | 68.11M |
| PE Ratio | 8.12 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 283,802 |
| Open | 318.90 |
| Previous Close | 317.00 |
| Day's Range | 312.90 - 325.00 |
| 52-Week Range | 233.50 - 556.00 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 440.14 (+40.67%) |
| Earnings Date | Aug 13, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ZEAL stock is "Buy." The 12-month stock price target is kr 440.14, which is an increase of 40.67% from the latest price.
News
Zealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorgan
JPMorgan lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 435 from DKK 460 and keeps an Overweight rating on the shares.
Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma
Zealand Pharma (ZLDPF) announced that it has entered into a royalty purchase and sale agreement with Royalty Pharma (RPRX) in exchange for Zealand Pharma’s economics related to rusfertide, a potential...
Zealand Pharma price target raised to DKK 420 from DKK 410 at Wells Fargo
Wells Fargo raised the firm’s price target on Zealand Pharma (ZLDPF) to DKK 420 from DKK 410 and keeps an Overweight rating on the shares. The company reported inline Q2…
Zealand Pharma Earnings Call Transcript: Q2 2026
Strong H1 2026 performance with double-digit weight loss from petrelintide, robust cash position, and key pipeline advances. Survodutide phase III trials met endpoints, and $100M royalty monetization boosts capital for strategic growth.
Zealand Pharma Quarterly report: Q2 2026
Zealand Pharma has published its Q2 2026 quarterly earnings report on August 13, 2026.
Zealand Pharma Slides: Q2 2026
Zealand Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Zealand Pharma downgraded to Hold from Buy at Jefferies
Jefferies downgraded Zealand Pharma (ZLDPF) to Hold from Buy with a price target of DKK 320, down from DKK 505. The firm is citing the absence of key value-crystallizing catalysts…
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on...
Zealand Pharma downgraded to Hold from Buy at Berenberg
Berenberg downgraded Zealand Pharma (ZLDPF) to Hold from Buy with a price target of DKK 300, down from DKK 825. The firm believes it will take longer than anticipated to…
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Zealand Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The event highlighted a shift in obesity drug development toward metabolic health, with survodutide and petrelintide showing promising profiles for liver fat reduction and tolerability. Flexible dosing and patient adherence are central, with major trials and pipeline expansion underway.
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Zealand Pharma lost a fifth of its market value on Monday after a late-stage trial found many patients stopped taking a weight-loss drug due to tolerability problems.
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Zealand Pharma's shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than riv...
Zealand Pharma announces Boehringer’s phase III results of survodutide
Zealand Pharma (ZLDPF) announced that Boehringer Ingelheim has reported positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide, Synchronize-1 and Synchronize-...
Zealand Pharma presents additional data from ZUPREME-1 trial
Zealand Pharma (ZLDPF) announced the presentation of additional data from its Phase 2 ZUPREME-1 trial, evaluating investigational petrelintide, at the 2026 Scientific Sessions of the American Diabetes...
Zealand Pharma price target raised to DKK 300 from DKK 275 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Zealand Pharma (ZLDPF) to DKK 300 from DKK 275 and keeps a Hold rating on the shares.
Zealand Pharma Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted progress on the Metabolic Frontier 2030 strategy, with major clinical data for petrelintide and survodutide expected at ADA. Strong financial positioning, new research partnerships, and a focus on patient adherence and market expansion were emphasized.
Zealand Pharma Earnings Call Transcript: Q1 2026
Q1 2026 saw major clinical and financial milestones, including strong phase II and III results for obesity candidates, robust cash reserves, and the launch of a $200 million share buyback. Strategic partnerships and a focus on R&D underpin a positive outlook for 2026.
Zealand Pharma Quarterly report: Q1 2026
Zealand Pharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zealand Pharma Slides: Q1 2026
Zealand Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Danish drug developer Zealand Pharma reported a smaller-than-expected first-quarter operating loss on Thursday, boosted by strong momentum in its obesity drug pipeline, and said it would l...
Zealand Pharma upgraded to Buy from Hold at SEB Equities
SEB Equities analyst Thomas Bowers upgraded Zealand Pharma (ZLDPF) to Buy from Hold with a DKK 475 price target
Zealand Pharma, Roche to advance petrelintide for weight management to Phase 3
Zealand Pharma A/S (ZLDPF) announced formal endorsement to advance petrelintide, an amylin analog for chronic weight management, into Phase 3 trials with its partner Roche (RHHBY). The initiation is p...
Zealand Pharma appoints Eric Rojas as VP, head of IR
Zealand Pharma (ZLDPF) announced the appointment of Eric Rojas, Vice President, Investor Relations, effective April 15, 2026. Eric will report to Henriette Wennicke, CFO, and will be based in Massachu...